Rezolute (RZLT) Reports Positive Interim Data for Ersodetug in Tumor HI Phase 3 Trial

Rezolute Inc. (NASDAQ:RZLT) announced on June 2, 2026, that the Phase 3 UpLIFT study of its investigational drug ersodetug met its primary endpoint in treating tumor hyperinsulinism (HI). The positive interim analysis led to the study's early halt for efficacy following a recommendation from an independent data monitoring committee. The trial enrolled patients with insulin-secreting tumors causing severe hypoglycemia. Ersodetug demonstrated a statistically significant reduction in hypoglycemic events compared to placebo, with a favorable safety profile. Rezolute plans to submit a New Drug Application to the FDA in the fourth quarter of 2026. Shares of RZLT rose sharply in pre-market trading, reflecting investor optimism about the first potential therapy for tumor HI.